Comparison of allele specific oligonucleotide-polymerase chain reaction and direct sequencing for high throughput screening of ABL kinase domain mutations in chronic myeloid leukemia resistant to imatinib

被引:0
作者
Kang, Ho-Young [1 ]
Hwang, Ji-Yeon [1 ]
Kim, Su-Hyun [1 ]
Goh, Hyun-gyung [1 ]
Kim, Myungshin [2 ]
Kim, Dong-Wook [1 ]
机构
[1] Catholic Univ Korea, Mol Hematol Lab, Div Hematol, Uijeongbu St Marys Hosp, Uijeongbu Si, Kyonggi Do, South Korea
[2] Catholic Univ Korea, Div Clin Pathol, St Marys Hosp, Seoul, South Korea
关键词
imatinib; CML; resistance; ASO-PCR; direct sequencing;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
To identify a fast and sensitive method for screening for mutations in patients with imatinib-resistant chronic myeloid leukemia (CML), we compared allele specific oligonucleotide-polymerase chain reaction (ASO-PCR) assay with conventional direct sequencing. Among the 68 imatinib resistant CML patients studied, 18 amino acid substitutions were detected in 44 patients by two assays. The sensitivity of ASO-PCR was superior to that of direct sequencing as it could detect one mutant allele in 100 similar to 100,000 wild type sequences. The fastness, simplicity, and sensitivity of ASO-PCR assays will be useful for routine monitoring of mutations, especially for frequently identified mutations.
引用
收藏
页码:659 / 662
页数:4
相关论文
共 17 条
[1]   High incidence of BCR-ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to imatinib [J].
Al-Ali, HK ;
Heinrich, MC ;
Lange, T ;
Krahl, R ;
Mueller, M ;
Müller, C ;
Niederwieser, D ;
Druker, BJ ;
Deininger, MWN .
HEMATOLOGY JOURNAL, 2004, 5 (01) :55-60
[2]   Mutation in the ATP-binding site of BCR-ABL in a patient with chronic myeloid leukaemia with increasing resistance to STI571 [J].
Barthe, C ;
Gharbi, MJ ;
Lagarde, V ;
Chollet, C ;
Cony-Makhoul, P ;
Reiffers, J ;
Goldman, JM ;
Melo, JV ;
Mahon, FX .
BRITISH JOURNAL OF HAEMATOLOGY, 2002, 119 (01) :109-111
[3]   High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance [J].
Branford, S ;
Rudzki, Z ;
Walsh, S ;
Grigg, A ;
Arthur, C ;
Taylor, K ;
Herrmann, R ;
Lynch, KP ;
Hughes, TP .
BLOOD, 2002, 99 (09) :3472-3475
[4]   Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis [J].
Branford, S ;
Rudzki, Z ;
Walsh, S ;
Parkinson, I ;
Grigg, A ;
Szer, J ;
Taylor, K ;
Herrmann, R ;
Seymour, JF ;
Arthur, C ;
Joske, D ;
Lynch, K ;
Hughes, T .
BLOOD, 2003, 102 (01) :276-283
[5]   Bcr-Abl inhibition as a modality of CML therapeutics [J].
Buchdunger, E ;
Matter, A ;
Druker, BJ .
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2001, 1551 (01) :M11-M18
[6]   Detection of ABL kinase domain mutations with denaturing high-performance liquid chromatography [J].
Deininger, MWN ;
McGreevey, L ;
Willis, S ;
Bainbridge, TM ;
Druker, BJ ;
Heinrich, MC .
LEUKEMIA, 2004, 18 (04) :864-871
[7]   Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification [J].
Gorre, ME ;
Mohammed, M ;
Ellwood, K ;
Hsu, N ;
Paquette, R ;
Rao, PN ;
Sawyers, CL .
SCIENCE, 2001, 293 (5531) :876-880
[8]   Molecular and chromosomal mechanisms of resistance to imatinib (ST1571) therapy [J].
Hochhaus, A ;
Kreil, S ;
Corbin, AS ;
La Rosée, P ;
Müller, MC ;
Lahaye, T ;
Hanfstein, B ;
Schoch, C ;
Cross, N ;
Berger, U ;
Gschaidmeier, H ;
Druker, BJ ;
Hehlmann, R .
LEUKEMIA, 2002, 16 (11) :2190-2196
[9]   Use of denaturing HPLC for detection of mutations in the BCR-ABL kinase domain in patients resistant to imatinib [J].
Irving, JAE ;
O'Brien, S ;
Lennard, AL ;
Minto, L ;
Lin, F ;
Hall, AG .
CLINICAL CHEMISTRY, 2004, 50 (07) :1233-1237
[10]  
KURZROCK R, 1988, NEW ENGL J MED, V319, P990